|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,395.00 TWD | +2.57% |
|
+16.74% | +196.81% |
| 18/06 | PharmaEssentia Rebuffs Media Report Speculating Profit, Revenue for 2026 | MT |
| 11/06 | PharmaEssentia Completes Enrollment for Phase III Primary Myelofibrosis Drug Study | MT |
| Market Cap | 52TCr 1.63TCr 1.42TCr 1.3TCr 1.22TCr 2.31TCr 1,54700Cr 2.34TCr 16TCr 6.09TCr 76TCr 6.1TCr 5.97TCr 2,61500Cr | P/E 2026 * |
48.5x | P/E 2027 * | 36x |
|---|---|---|---|---|---|
| Enterprise Value | 49TCr 1.54TCr 1.35TCr 1.24TCr 1.15TCr 2.19TCr 1,46800Cr 2.22TCr 15TCr 5.77TCr 72TCr 5.79TCr 5.66TCr 2,48100Cr | EV / Sales 2026 * |
20x | EV / Sales 2027 * | 14.4x |
| Free-Float |
78.15% | Yield 2026 * |
0.06% | Yield 2027 * | 0.09% |
| 1 day | +2.57% | ||
| 1 week | +16.74% | ||
| Current month | +4.10% | ||
| 1 month | +54.66% | ||
| 3 months | +120.73% | ||
| 6 months | +181.82% | ||
| Current year | +196.81% |
| 1 week | 1,205 |  | 1,405 |
| 1 month | 885 | | 1,405 |
| Current year | 470 | | 1,405 |
| 1 year | 438.85 | | 1,405 |
| 3 years | 246.91 | | 1,405 |
| 5 years | 62.18 | | 1,405 |
| 10 years | 48.3 | | 1,405 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 01/01/2003 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 14/10/2015 |
Albert Qin
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Ching Liu Chan
CHM | Chairman | - | 01/09/2003 |
Cheng Ku Huang
BRD | Director/Board Member | - | - |
Chao Ho Chen
BRD | Director/Board Member | - | 30/06/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.57% | +16.74% | +171.12% | +355.99% | 1.63TCr | |
| -0.34% | +4.44% | +77.93% | +134.46% | 5.87TCr | |
| -3.12% | +3.48% | +72.79% | +94.67% | 5.39TCr | |
| +3.86% | +8.38% | -9.90% | -9.62% | 2.47TCr | |
| +4.30% | +6.82% | +13.60% | +428.91% | 2.42TCr | |
| +4.63% | +13.86% | +45.81% | -1.26% | 1.88TCr | |
| -0.32% | +8.89% | +44.60% | -27.36% | 1.76TCr | |
| +3.50% | +4.92% | +26.07% | +192.26% | 1.4TCr | |
| +5.95% | +18.42% | +41.67% | - | 1.39TCr | |
| +2.67% | +2.79% | +75.95% | +128.61% | 1.22TCr | |
| Average | +2.33% | +8.24% | +55.96% | +144.07% | 2.54TCr | |
| Weighted average by Cap. | +1.09% | +7.00% | +58.53% | +135.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.46TCr 77Cr 67Cr 62Cr 58Cr 109.53Cr 7.35TCr 111.38Cr 745.94Cr 289.09Cr 3.61TCr 289.91Cr 283.61Cr 12TCr | 3.36TCr 105.22Cr 92Cr 84Cr 79Cr 149.26Cr 10TCr 151.78Cr 1.02TCr 393.96Cr 4.91TCr 395.09Cr 386.5Cr 17TCr |
| Net income | 1.07TCr 34Cr 29Cr 27Cr 25Cr 48Cr 3.21TCr 49Cr 325.55Cr 126.16Cr 1.57TCr 126.53Cr 123.78Cr 5.42TCr | 1.46TCr 46Cr 40Cr 37Cr 34Cr 65Cr 4.35TCr 66Cr 441.02Cr 170.92Cr 2.13TCr 171.41Cr 167.68Cr 7.34TCr |
| Net Debt | -2.65TCr -83Cr -73Cr -67Cr -62Cr -117.96Cr -7.92TCr -119.96Cr -803.39Cr -311.35Cr -3.88TCr -312.24Cr -305.46Cr -13TCr | -3.47TCr -108.88Cr -95Cr -87Cr -81Cr -154.45Cr -10TCr -157.06Cr -1.05TCr -407.65Cr -5.08TCr -408.81Cr -399.93Cr -18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | NT$1,395.00 | +2.57% | 26,00,601 |
| 01/26/01 | NT$1,360.00 | +1.49% | 26,75,199 |
| 30/26/30 | NT$1,340.00 | +5.51% | 51,21,807 |
| 29/26/29 | NT$1,270.00 | +9.96% | 29,07,656 |
| 26/26/26 | NT$1,155.00 | -3.35% | 28,26,807 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6446 Stock
Select your edition
All financial news and data tailored to specific country editions
